Pulse intravenous cyclophosphamide therapy for dermatologic disorders

Lindy P. Fox, Amit G. Pandya

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Cyclophosphamide is a potent immunosuppressive agent, is a well-established treatment modality for a variety of disorders. Pulse intravenous cyclophosphamide has been shown to be efficacious for several dermatologic disorders, particularly pemphigus vulgaris, with a low incidence of toxicity reported. As reported earlier, studies performed on the use of pulse intravenous cyclophosphamide in the treatment of a variety of dermatology-related diseases strongly suggest that the toxicities frequently noted with the use of oral cyclophosphamide therapy may be significantly less common with pulse intravenous administration of cyclophosphamide. The short follow-up period of patients treated with this modality so far, however, requires constant vigilance for the development of side effects, particularly secondary malignancy. At this time, pulse intravenous cyclophosphamide is a promising treatment modality with an acceptable risk profile for moderate-to-severe dermatologic diseases recalcitrant to standard therapy. Prospective comparative trials are needed to assess further the efficacy and toxicity of this therapy.

Original languageEnglish (US)
Pages (from-to)459-473
Number of pages15
JournalDermatologic Clinics
Volume18
Issue number3
DOIs
StatePublished - Jan 1 2000

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Pulse intravenous cyclophosphamide therapy for dermatologic disorders'. Together they form a unique fingerprint.

  • Cite this